Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CLL Town Meeting Morning Session Replay in Houston, Texas
Watch replay of the morning session of the town meeting, “Living Well with Chronic Lymphocytic Leukemia: Education, Empowerment and Learning from Others,” which features leading CLL experts discussing... Author: patientpower Added: 01/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2016 Category: Cancer & Oncology Source Type: podcasts

The use of venetoclax (ABT-199) in the treatment of CLL
Peter Hillmen, MBChB, PhD from St. James' University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia (CLL), as a single-agent and in... Author: PatientPowerEU Added: 01/08/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2016 Category: Cancer & Oncology Source Type: podcasts

Overview of new therapies in CLL presented at ASH 2015
George Follows, MA, PhD, MRCP, FRCPath from Cambridge University Hospital, Cambridge, UK, gives an overview of the new chronic lymphocytic leukemia (CLL) treatments being presented at the American Soc... Author: PatientPowerEU Added: 01/08/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2016 Category: Cancer & Oncology Source Type: podcasts

Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111 at ASH 2015 Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CL... Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib - Rituximab Combination for Relapsed CLL Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015 Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

How Will the Idelalisib + Ofatumumab Trial Affect Planning in CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL Author: ASHReport Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Expert Perspectives: Chronic Lymphocytic Leukemia (CLL)
Expert Perspectives was recorded at the conclusion of the chronic lymphocytic leukemia sessions on the second day of Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies ... Author: imedex Added: 11/28/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 28, 2015 Category: Cancer & Oncology Source Type: podcasts

Evaluating sustained adherence to ibrutinib in previously treated chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibruti... Author: EMJ Added: 08/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 25, 2015 Category: Cancer & Oncology Source Type: podcasts

Hockey Star Paul Henderson: I’ve Got Today
Former National Hockey League (NHL) hockey player Paul Henderson gives an update about his life with chronic lymphocytic leukemia (CLL). Paul shares his outlook on living well with CLL, what he feels ... Author: patientpower Added: 07/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2015 Category: Cancer & Oncology Source Type: podcasts

EHA 2015: The treatment of relapsed/refractory chronic lymphocytic leukemia
Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, summarises her highlights of the 20th Congress of the European Hematology Association (EHA), including the results of a phase 1b... Author: VJHemOnc Added: 07/14/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 14, 2015 Category: Cancer & Oncology Source Type: podcasts

Advances in the treatment of CLL at ASCO 2015
At ASCO 2015, Prof. Dr. med. Stephan Stilgenbauer reviews the changing chronic lymphocytic leukemia (CLL) treatment landscape. With the development of many new agents, researchers are now investigatin... Author: VJHemOnc Added: 07/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Towards targeted therapy in chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at ASCO 2015
Jacqueline Barrientos, MD, summarises recent progress in the treatment of chronic lymphocytic leukaemia at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. ––– European Medi... Author: EMJ Added: 07/02/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2015 Category: Cancer & Oncology Source Type: podcasts

Why Watch and Wait Is Necessary
Why is the watch-and-wait period necessary for many people with chronic lymphocytic leukemia (CLL)? Dr. Javier Munoz, from Banner MD Anderson Cancer Center, explains the reasoning behind this phase, w... Author: patientpower Added: 06/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2015 Category: Cancer & Oncology Source Type: podcasts